Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients

Pyrotinib Plus Vinorelbine in Metastatic HER2-positive Breast Cancer Patients- a Multicenter Retrospective Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04517305

Enrollment

Registered

2020-08-18

Start date

2018-05-15

Completion date

2021-05-15

Last updated

2021-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Pyrotinib

Brief summary

To evaluate the patterns and treatment outcomes of pyrotinib plus vinorelbine in the real world.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* woman, age \> 18 years old * diagnosed with HER2 +Metastatic Breast Cancer * pyrotinib plus vinorelbine for at least one cycle, starting from 2018.05-2020.05 * available medical history

Exclusion criteria

* medical history was incomplete

Design outcomes

Primary

Measure	Time frame	Description
PFS	6 weeks	Progression free survival
Adverse events	6 weeks	Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)

Countries

China

Outcome results